AMYRIAD IS ADDRESSING THE CORE SYMPTOMS OF AD: COGNITION AND GLOBAL FUNCTION

We are developing two series of small, synthetic molecules. Each series enhances neurotransmission in a different way.

Our 100 Series lead compound, AD101, demonstrated statistically significant improvement in both core symptoms of AD in Placebo-controlled, Double-blind, Phase 2 Proof of Concept Trials. Efficacy was accompanied by a superb profile of safety and tolerability that was not distinguishable from that of the placebo-treated cohort.